Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTCOFF: PK Comparison of Tacrolimus Formulations
NCT02339246Phase 3Completed
- Sponsor
- Veloxis Pharmaceuticals
- Start
- Jan 2015
- Primary completion
- Mar 2015
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Envarsus XR in kidney transplant rejection, sponsored by Veloxis Pharmaceuticals. Started Jan 2015; status: completed.
02
Drugs
Envarsus XR
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT02339246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02339246.